18/08/2026 Biocon announced US FDA approval of Yesintek® single dose prefilled autoinjector Abcuro announced a $66 million series D financing to advance ulviprubart in inclusion body myositis Biocon announced US FDA approval of Yesintek® single dose prefilled autoinjector (Ref) Biocon announced that its US Subsidiary had received supplemental US FDA approval for Yesintek® (ustekinumab-kfce) as a single-dose prefilled autoinjector. The approval covered 45 mg/0.5 mL and 90 mg/m

24/02/2026 Abcuro announced topline results from its Phase 2/3 study of ulviprubart in patients with inclusion body myositis J&J submitted sBLA to the US FDA for approval of IMAAVY® for warm autoimmune hemolytic anemia Abcuro announced topline results from its Phase 2/3 study of ulviprubart in patients with inclusion body myositis ( Ref ) Abcuro announced topline results from its Phase 2/3 MUSCLE/ NCT05721573 study, which evaluated ulviprubart (ABC008; anti-KLRG1) for the tre